The type 1 research year in review: what genuinely moved in 2025
On 19 December 2025 Breakthrough T1D UK summed up a landmark year: teplizumab licensed, islet-cell results, UK screening data and smart-insulin progress.
The honest one-line version of 2025 is real progress on one front and hopeful groundwork on several others, with no cure. A UK charity, Breakthrough T1D, gathered the year’s Type 1 research highlights. The standout is teplizumab, the first drug that can delay Type 1 rather than only manage it, which reached approval.
- The one that crossed the line was teplizumab, called the first disease-modifying therapy, meaning it changes the disease itself rather than only replacing insulin.
- Cell therapies (lab-grown or engineered insulin-making cells) reported encouraging early results, but stayed at the small, first-in-human stage.
- UK screening research looked at spotting Type 1 before symptoms, which is what makes a delay drug useful in the first place.
- Smart insulin, an insulin meant to switch on and off with your glucose, moved forward in the lab but is not something you can be prescribed.
The one that crossed the line
Most research news is a step, not an arrival. In 2025, one thing genuinely crossed from lab to licence: teplizumab, approved as the first treatment that can delay Type 1 developing rather than simply managing it once it is here. For people found early, usually the relatives of someone who already has Type 1, that can mean extra time before insulin. It is worth being precise about why this counts as a landmark. For a hundred years, Type 1 care has meant replacing the insulin the body no longer makes. A drug that changes the timeline of the disease itself is a different kind of thing, even though it is only a delay, and only for people caught early.
The news that is not ready yet
The rest of the year’s highlights are real, but they are research, not treatments. Engineered insulin-making cells that survive without harsh anti-rejection drugs made headlines, and deservedly so, but at the scale of a few patients watched over months. Screening studies explored how to catch Type 1 before it shows up, which pairs naturally with a delay drug. Smart insulin, which would ease off as your glucose drops and step up as it rises, kept progressing in the lab. None of these is something a UK clinic can offer you now. Filing them under hopeful groundwork, rather than imminent cure, is simply the accurate place to keep them.